Summary:
- Hy2Care, a company based in the Netherlands, secured €4.5M in funding for its injectable hydrogel technology.
- The funding includes support from the European Innovation Council (EIC) Fund and existing shareholders.
- Hy2Care plans to use the funds for preparations for a clinical trial in the United States.
Article:
Injectable Hydrogel Company, Hy2Care, Secures €4.5M in Funding
Hy2Care, a company headquartered in Geleen, the Netherlands, has successfully raised €4.5M in funding to support its innovative injectable hydrogel technology. The funding round was a significant milestone for the company, with half of the investment coming from the European Innovation Council (EIC) Fund as part of the EIC Accelerator program. The remaining funds were contributed by Hy2Care’s existing shareholders, led by Brightlands Venture Partners, along with new investors such as LIOF, the regional development agency for Limburg.
The primary focus of the funding will be to prepare for an upcoming clinical trial in the United States. This trial will be a crucial step in advancing Hy2Care’s technology and bringing it closer to market readiness. CEO Leo Smit expressed optimism about the company’s progress and the potential impact of their injectable hydrogel on the medical field.
Hy2Care is a spin-off company of the MIRA Institute at the University Twente in the Netherlands, specializing in biomedical and chemical engineering. The company’s CartRevive hydrogel implant has already completed patient enrollment for its EU trial in 2024, with expectations of receiving CE marking and European market approval by early 2026. The success of this trial will pave the way for further development and commercialization of Hy2Care’s groundbreaking technology.
In conclusion, Hy2Care’s recent funding achievement marks a significant step forward in the company’s mission to revolutionize cartilage repair through its injectable hydrogel technology. With the support of investors and ongoing clinical trials, Hy2Care is well-positioned to make a lasting impact on the field of regenerative medicine.
Published by FinSMEs on 19/05/2025
